Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.P. Link, S.S. Donaldson.
The lymphomas and lymphadenopathy.
Hematology of infancy and childhood, 5th ed, pp. 1324-1339
[2.]
A.T. Magrath.
Malignant non-Hodgkin's lymphomas in children.
Principles and practice of pediatric oncology, 4th ed, pp. 661-705
[3.]
J.T. Sandlund, J.R. Downing, W.M. Crist.
Medical progress: non-Hodgkin's lymphomas in chidhood.
N Engl J Med, 334 (1996), pp. 1238-1248
[4.]
J. Mora, D.A. Filippa, J. Qin, N. Wollner.
Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Cancer, 98 (2003), pp. 1283-1291
[5.]
W.C. Lavely, D. Delbeke, J.P. Greer, D.S. Morgan, D.W. Byrne, R.R. Price, et al.
FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first line chemotherapy.
Int J Radiat Oncol Biol Phys, 57 (2003), pp. 307-315
[6.]
M.S. Cairo, M.D. Krailo, M. Morse, R.J. Hutchinson, R.E. Harris, C.R. Kjeldsberg, et al.
Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate (“Orange”) in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report.
Leukemia, 16 (2002), pp. 594-600
[7.]
C. Patte, A. Laplanche, A.I. Bertozzi, A. Baruchel, D. Frappaz, C. Schmitt, et al.
Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
J Clin Oncol, 20 (2002), pp. 441-448
[8.]
J.Y. Tang, C. Pan, J. Chen, H. Chen, Y. Wu, H. Xue, et al.
Outcome of B-cell non-Hodgkin lymphoma protocol CCCG-B NHL97: a report from Chinese multi-center cooperative group.
Med Pediatr Oncol, 39 (2002), pp. 212-214
[9.]
R. Sposto, A.T. Meadows, R.R. Chilcote, P.G. Steinherz, C. Kjeldsberg, M.D. Kadin, et al.
Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin- COMP: a report from the Children's Cancer Group.
Med Pediatr Oncol, 37 (2001), pp. 432-441
[10.]
K. Siedemann, M. Tiemann, M. Schrappe, E. Yakisan, I. Simonitsch, G. Janka-Schaub, et al.
Short-pulse B-non-Hodgkin lymphoma- type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM 90.
Blood, 97 (2001), pp. 3699-3706
[11.]
P.J. Bierman, J.W. Sweetenham, F.R. Loberiza, G. Taghipour, H.M. Lazarus, J.D. Rizzo, et al.
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation. the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
J Clin Oncol, 21 (2003), pp. 3744-3753
[12.]
M.J. Stuart, N.S. Chao, S.J. Homing, R.M. Wong, R.S. Negrin, L.J. Johnston, et al.
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Bone Marrow Transplant, 7 (2001), pp. 552-560
[13.]
A. Reiman, J.E. Powell, K.J. Flavell, R.G. Grundy, J.R. Mann, S. Parkes, et al.
Seasonal differences in the onset of the EBV-positive and negative forms of pediatric Hodgkin's lymphoma.
Br J Cancer, 89 (2003), pp. 1200-1201
[14.]
M.M. Hudson, S.S. Donaldson.
Hodgkin's disease.
Principles and practice of pediatric oncology, 4th ed, pp. 637-660
[15.]
S.B. Murphy, E.R. Morgan, H.M. Katzenstein, M. Kletzen.
Results of little or no treatment for lymphocite-predominant Hodgkin disease in children and adolescents.
J Pediatr Hematol Oncol, 25 (2003), pp. 684-687
[16.]
B. Pellegrino, M.J. Terrier-Lacombe, O. Oberlin, T. Leblanc, Y. Perel, Y. Bertrand, et al.
Lymphocite-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection.a Study of the French Society of Pediatric Oncology.
J Clin Oncol, 21 (2003), pp. 2948-2952
[17.]
N.L. Harris.
Hodgkin's disease: classification and differencial diagnosis.
Mod Pathol, 12 (1999), pp. 159-175
[18.]
P.A. Ganz, C.M. Moinpour, D.K. Pauler, A.B. Kornblith, E.R. Gaynor, S.P. Balcerzak, et al.
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.
J Clin Oncol, 21 (2003), pp. 3512-3519
[19.]
R.S. Smith, Q. Chen, M.M. Hudson, M.P. Link, L. Kun, H. Weinstein, et al.
Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy.
J Clin Oncol, 21 (2003), pp. 2026-2033
[20.]
H. Ekert, D. Ashley, et al.
Randomized comparison of low-dose involved- field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy, by Nachman.
J Clin Oncol, 21 (2003), pp. 1192
[21.]
C.L. Schwart.
The management of Hodgkin's disease in the young child.
Curr Opin Pediatr, 15 (2003), pp. 10-16
[22.]
P.L. Zinzani, M. Tani, A. Gabriele, F. Gherlinzoni, A. De Vivo, P. Ricci, et al.
High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience.
Haematologica, 88 (2003), pp. 522-558
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados